Form 4: Kalaris Therapeutics Officer Acquires Shares and Options Following Merger

Matthew Feinsod, Chief Medical Officer of Kalaris Therapeutics, reports acquisition of shares and options following the merger with Kalaris Tx, Inc.

Summary

• Matthew Feinsod, Chief Medical Officer of Kalaris Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the acquisition of 4,030 shares of common stock on March 18, 2025, resulting from the merger with Kalaris Tx, Inc.
• These shares were issued in exchange for outstanding shares of KTx common stock at an exchange ratio of 0.2016 shares of Kalaris Therapeutics for each share of KTx.
• Feinsod also acquired a stock option to purchase 28,224 shares of common stock at an exercise price of $0.85, assumed in connection with the merger.
• The option vests over four years beginning June 17, 2024, with 1/48th of the shares vesting monthly.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports a standard transaction following a merger. The acquisition of shares by an officer can be seen as a slightly positive sign.

Positives

• The acquisition of shares and options by a key officer could be interpreted as a sign of confidence in the company's future following the merger.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Key Dates